Table 3.
List of metabolites that were significantly different in the pre-EEN treatment group (PA) compared to the healthy controls (HC), based on an OPLS-DA model. All marker compounds were normally distributed according to a Q-Q test.
| Putative Metabolite | Pathway | (PA/HC) | p-Value | q-Value | AUC | VIP Total | VIP (Pred./Ortho.) |
|---|---|---|---|---|---|---|---|
| Ornithine isomer | unknown | 0.15 | 7.82 × 10−3 | 2.67 × 10−2 | 0.84 | 1.85 | 4.28 |
| C20 sphingenine | Sphingoid bases | 6.54 | 2.03 × 10−2 | 3.92 × 10−2 | 0.75 | 1.81 | 2.82 |
| Tyrosine | Tyrosine metabolism | 0.37 | 2.64 × 10−2 | 4.98 × 10−2 | 0.83 | 1.63 | 1.84 |
| SM (d18:1/24:1) | Ceramide phosphocholines (sphingomyelins) | 14.52 | 3.28 × 10−3 | 2.67 × 10−2 | 0.87 | 1.26 | 1.08 |
| Eicosatrienoic acid | Biosynthesis of unsaturated fatty acids | 16.18 | 3.48 × 10−4 | 4.67 × 10−3 | 0.88 | 1.07 | 1.53 |
| Docosatetraenoic acid | Biosynthesis of unsaturated fatty acids | 20.32 | 9.11 × 10−4 | 6.15 × 10−3 | 0.92 | 1.02 | 1.01 |
| Arachidonic acid | Fatty Acids and Conjugates | 18.05 | 4.79 × 10−3 | 1.94 × 10−2 | 0.88 | 0.99 | 2.91 |
| Octadecenoylsphingenine | Ceramides | 11.88 | 5.31 × 10−5 | 1.08 × 10−3 | 0.94 | 0.89 | 1.21 |